Samsung Bioepis and Phrontline to co-develop novel bispecific, dual-payload ADC TJ108 under global pact

On October 21, Samsung Bioepis, a subsidiary of the Samsung Group, and Phrontline Biopharma entered into a global collaboration agreement.

Under the agreement, the two parties will jointly develop, manufacture, and commercialize two ADC assets, including TJ108 and another product yet to be named. Additionally, Samsung Bioepis has obtained an exclusive license for a topoisomerase-1 inhibitor (TOP1i) payload, which will be applied to its own ADC pipeline.

TJ108 is a bispecific, dual-payload ADC targeting HER3 and EGFR, incorporating both a TOP1i and a tubulin inhibitor as cytotoxic payloads. The program is currently in the preclinical development stage.

In return, Phrontline will receive an upfront payment and will be eligible for additional milestone payments tied to development and regulatory achievements. The specific financial details have not been disclosed.